Voronoi Inc
310210
Company Profile
Business description
Voronoi Inc is a biotech company that develops novel kinase inhibitors and targets protein degraders. It is principally focused on developing targeted therapies for anticancer drugs such as lung and breast cancer. Its pipeline products are: VRN11, VRN16, VRN10, VRN19, VRN07, VRN04, VRN06, and others.
Contact
32 Songdo Science-ro
18th floor, S Building
Songdo-dong, Songdo Techno Park IT Center
Yeonsu-gu
Incheon
KORT: +82 328304855
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
146
Stocks News & Analysis
stocks
Navigating the ASX dividend landscape in 2026
Dividend yields are well below the 10-year average. Here’s how to navigate lower yields in 2026.
stocks
Meta stock has struggled amid AI spending concerns. Is it a buy?
Meta stock has lost ground as investors raise concern over capital expenditures and risky AI strategies.
stocks
Netflix Earnings: Strong, as expected; 2026 guidance confirms decelerating growth
We think Netflix stock is moderately overvalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,172.50 | 12.40 | 0.14% |
| CAC 40 | 8,163.34 | 94.17 | 1.17% |
| DAX 40 | 24,837.53 | 276.55 | 1.13% |
| Dow JONES (US) | 49,072.24 | 583.65 | 1.20% |
| FTSE 100 | 10,191.40 | 53.31 | 0.53% |
| HKSE | 26,629.96 | 44.90 | 0.17% |
| NASDAQ | 23,224.82 | 270.50 | 1.18% |
| Nikkei 225 | 53,688.89 | 914.25 | 1.73% |
| NZX 50 Index | 13,556.87 | 139.70 | 1.04% |
| S&P 500 | 6,873.77 | 1.85 | -0.03% |
| S&P/ASX 200 | 8,848.70 | 12.80 | 0.14% |
| SSE Composite Index | 4,122.58 | 5.64 | 0.14% |